Search Medical Condition
Please enter condition
Please choose location from dropdown

Waldenstrom Macroglobulinemia Clinical Trials

A listing of Waldenstrom Macroglobulinemia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (51) clinical trials

The Comparison of RCD Versus BCD in Newly Diagnosed Waldenstr m Macroglobulinemia

Newly diagnosed WM patients will be randomly assigned to BCD or RCD group for introduction chemotherapy. Chemotherapeutic response will be evaluated after 3 cycles. If a PR or better response achieves, addition 3 cycles will be given. If not, patients will be crossed to control group for another 3 cycles. ...

Phase

PCD Versus RCD for the Treatment of Patients With Waldenstrom's Macroglobulinemia

This is an open-label, single-centre, randomised study, looking at a series of 40 patients up to the age of 75 with newly diagnosed Waldenstrom's macroglobulinemia (WM) not previously treated. Patients will receive RCD or PCD combination as induction treatment followed by rituximab or velcade maintenance therapy, as the investigators try ...

Phase

The Efficacy of TCD Following by TP Maintenance Therapy in Newly Diagnosed WM

Enrolled patients will accept maximum 8 cycles of thalidomide plus cyclophosphamide and dexamethasone. if a partial remission response or better is achieved, thalidomide plus prednisone maintenance therapy will be given for no more than two years.

Phase

Study of VTD in Waldenstrom's Macroglobulinemia

This study is a phase 2, single-arm, open-label, multi-institutional trial to evaluate the efficacy of combination therapy of bortezomib, thalidomide, and dexamethasone in patients with newly diagnosed Waldenstrom's macroglobulinemia and lymphoplasmacytic lymphoma.

Phase

Comparison of ASCT and Conventional Chemotherapy in High Risk Waldenstr m Macroglobulinemia

WM patients with partial response after introduction chemotherapy will be recommended to adopt autologous stem cell transplantation or receive conventional chemotherapy (dependent on patient's choices). After transplantation or conventional chemotherapy, maintenance therapy with rituximab or thalidomide plus prednisone will be given for less than two years.

Phase

Study of Safety Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma Chronic Lymphocytic Leukemia and Waldenstrom's Macroglobulinemia

This is a phase I study of BTK inhibitor CT-1530 in patients with relapsed or refractory B cell non-Hodgkin lymphoma (B-NHL), chronic lymphocytic leukemia (CLL) or Waldenstrom's macroglobulinemia (WM). The purpose of the study is to determine the MTD/RP2D of CT-1530, and evaluate its safety and tolerability as monotherapy in ...

Phase

Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas

PRIMARY OBJECTIVES: I. To evaluate the safety of brentuximab vedotin and rituximab in patients with lymphoid malignancies that are cluster of differentiation (CD) 30 positive (+) and/or Epstein-Barr virus (EBV)+, and to determine the recommended phase 2 dose (RP2D) of the combination. (Phase I) II. To evaluate the efficacy, as ...

Phase

Collecting Stem Cells in Patients With Waldenstrom's Macroglobulinemia

OBJECTIVES: - Harvest and store adequate CD34+ stem cells from patients with Waldenstrom's macroglobulinemia (WM) for potential future use in transplantation strategies. - Evaluate the ability to harvest stem cells after therapy for WM (e.g., fludarabine-based chemotherapy) by evaluating the number of days to adequate harvest. - Collect aliquots of ...

Phase N/A

TLR8 Agonist VTX-2337 in Combo With Local Radiation in Low-Grade B-cell Lymphomas

The primary objective is to determine the local and systemic anti-tumor effects of intratumoral injection of VTX-2337, a TLR8 agonist, in combination with low-dose local radiation at a single tumor site, in patients with recurrent b-cell lymphoma.

Phase

Vincristine Sulfate Liposome Injection (Marqibo ) Bendamustine and Rituximab Phase I Trial in Indolent B-cell Lymphoma

Bendamustine-rituximab is a standard chemotherapy regimen for treatment of many indolent B-cell lymphomas, but most patients experience a recurrence of the lymphoma. Vincristine sulfate has been a traditional component of chemotherapy regimens in non-Hodgkin lymphoma and it is possible that adding it to the bendamustine-rituximab regimen might provide a better ...

Phase